We're looking forward to the upcoming LSPN North America Fall 2024 conference, that's taking place in San Francisco in October.
Now in its sixth year, the theme for this year's conference is 'protecting and leveraging your IP across the life cycle of innovation'. The programme will deliver an overview of the latest rulings and legislative developments, as well as providing a platform for professionals to share their solutions to everyday IP challenges.
We're proud to sponsor this event and help bring together in-house patent counsel from leading pharmaceutical and biotechnology companies.
Date: 15 – 16 October 2024
Location: San Francisco, USA
On the conference agenda
Roundtable: Strategies for protecting CRISPR, CAR-T and other immunotherapies
We're hosting a roundtable on Day 2 of the conference, focusing on strategies for protecting CRISPR, CAR-T and other immunotherapies.
Time: 11:20-12:55 (EDT)
Date: Wednesday 16 October 2024
Meet the HLK team attending LSPN North America Fall 2024
At HLK, we enjoy developing long-standing, collaborative relationships, and aim to understand our client's business needs. Our team has a wealth of experience across the IP lifecycle in the pharma and life sciences field.
Meet our experts who'll be at the conference.
Joseph Lenthall
Partner | UK and European Patent Attorney | UPC Representative
Joe is a leading Chemistry & Life Sciences EPO Opposition and Appeal specialist. He is particularly adept at handling complex multi-party Oppositions and Appeals. Recent highlights include defending EP patents covering small molecule splicing modulator therapies, CRISPR gene-editing therapies, protein kinase inhibitors, companion diagnostics, ADCs, thin film drug delivery technology, and foods incorporating recombinant proteins.
Joe's opposition practice feeds back into the team's drafting and prosecution practice to ensure robust patent protection for commercially significant products. Joe has particular expertise in the fields of therapeutics (including secondary protection through formulations, drug delivery, dosage regimes and patient stratification), diagnostics, biocatalysis and microbial fermentation.
Catherine Coombes
Partner | UK and European Patent Attorney
A CRISPR specialist, Cath has worked on some of the earliest CRISPR patents exploiting its role in bacterial immunity and has been at the forefront on this technology ever since. As such, Cath has extensive experience in opposition matters, due diligence, and drafting across the wide array of technologies to which CRISPR has been applied. Cath has provided education to fellow patent attorneys, has written numerous articles and has provided commentary on CRISPR IP to leading scientific and IP journals such as Nature, Science, The Scientist, IAM and LSIPR.
Prior to joining the IP profession Cath's background was in the scale up of active pharmaceutical ingredients and in the downstream processing of food ingredients.
Caroline Day
Partner | UK and European Patent Attorney
As a speaker at a variety of high-profile seminars and author of numerous articles, Caroline is a leading expert in the field of protecting Artificial Intelligence (AI) and Machine Learning. Caroline's professionalism, pragmatism, and solutions-oriented approach means that she earns the deep trust from her clients and maintains many long-standing relationships with a number of global businesses. Thanks to time spent working in-house in the past, Caroline developed a strong understanding of the strategic and operational challenges faced by in-house counsel and is uniquely placed to help solve those challenges.